

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Cameron	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Costantini	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Davis	Speaker	<ul style="list-style-type: none"> Akcea, Alnylam Pharmaceuticals, Amgen, Boehringer Ingelheim, Ferring, Janssen, Novartis, Pfizer, Takeda Akcea, Boehringer Ingelheim, Pfizer, Servier, Takeda 	<ul style="list-style-type: none"> Consultant, Speaker Grant Funding
Deswal	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Hardaway	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Khedraki	Moderator, Peer Reviewer, Planning Committee, Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Kuo	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Lanfeer	Speaker	<ul style="list-style-type: none"> Amgen, AstraZeneca, Cytokinetics, Janssen, Lily, Somalogic Abbott, Amgen, Cytokinetics, Janssen, Martin Pharmaceuticals, Ortho Diagnostics 	<ul style="list-style-type: none"> Research Support Consultant
Mahindra	Course Director, Moderator, Speaker	<ul style="list-style-type: none"> GlaxoSmithKline Bristol Myers Squibb, Epizyme, Karyopharm Therapeutics 	<ul style="list-style-type: none"> Advisor/Speaker Advisor
Mitter	Speaker	<ul style="list-style-type: none"> Abbott, Cowen & Co 	<ul style="list-style-type: none"> Honorarium
Mohan	Course Director, Moderator, Speaker	<ul style="list-style-type: none"> Axon Therapeutics, CORVIA, V-Wave CareDX, Eidos Therapeutics Akcea, Alnylam Pharmaceuticals, Pfizer 	<ul style="list-style-type: none"> Research Consultant Speaker
Rosenthal	Moderator, Speaker	<ul style="list-style-type: none"> Alnylam Pharmaceuticals, Pfizer 	<ul style="list-style-type: none"> Advisory Board
Srivastava	Planning Committee, Speaker	<ul style="list-style-type: none"> Abbott 	<ul style="list-style-type: none"> Speaker
Tamarappoo	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Tripuraneni	Speaker	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Witteles	Speaker	<ul style="list-style-type: none"> • Alnylam Pharmaceuticals, Eidos Therapeutics, Ionis Pharmaceuticals, Janssen Oncology, Pfizer, Regeneron Pharmaceuticals 	<ul style="list-style-type: none"> • Advisor
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.